Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled DMT for Major Depressive Disorder
NCT07562191Phase 2Recruiting
- Sponsor
- Universidade Federal do Rio Grande do Norte
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DMT in major depressive disorder (MDD), sponsored by Universidade Federal do Rio Grande do Norte. Started Aug 2026; status: recruiting.
02
Drugs
DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07562191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562191.